Medroxyprogesterone (CAS 520-85-4) -Medroxyprogesterone Acetate

Medroxyprogesterone (CAS 520-85-4) is a high-purity pharmaceutical API classified as a potent synthetic progestin, featuring a modified progesterone molecular structure with enhanced bioavailability and longer half-life than endogenous progesterone. It binds to progesterone receptors in target tissues (uterus, breast, hypothalamus) to mimic natural progesterone effects—regulating menstrual cycles, preventing endometrial hyperplasia, and suppressing ovulation. Unlike natural progesterone, its synthetic form offers stable oral absorption, making it adaptable for diverse hormonal formulations.

It caters to the core needs of hormone therapy manufacturers, gynecological drug developers, and reproductive health supply chains. Widely applied in treatments for menstrual irregularities, endometriosis, menopausal hormone therapy (MHT), and contraception, it aligns with demand for versatile, well-tolerated hormonal solutions. Produced under strict GMP standards, each batch undergoes rigorous purity and potency testing to meet international pharmacopoeia requirements, ensuring consistency for clinical use. For businesses prioritizing evidence-based hormonal therapies, this Medroxyprogesterone API serves as a critical raw material for advancing reproductive and gynecological medication development.